<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77482">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02096861</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P13 3.4</org_study_id>
    <secondary_id>2013-004497-10</secondary_id>
    <nct_id>NCT02096861</nct_id>
  </id_info>
  <brief_title>Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 Compared to Remicade in Patients With Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess noninferiority in efficacy and to assess overall safety of CT P13
      compared to Remicade in patients with active Crohn's disease up to Week 54.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">February 15, 2017</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy evaluated by Assessment of Crohn's disease activity index -70 response</measure>
    <time_frame>at Week 6</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>CT-P13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CT-P13, switch to Remicade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Remicade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Remicade, switch to CT-P13</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P13</intervention_name>
    <description>CT-P13 (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose</description>
    <arm_group_label>CT-P13</arm_group_label>
    <arm_group_label>CT-P13, switch to Remicade</arm_group_label>
    <arm_group_label>Remicade, switch to CT-P13</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Remicade</intervention_name>
    <description>Remicade (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose</description>
    <arm_group_label>CT-P13, switch to Remicade</arm_group_label>
    <arm_group_label>Remicade</arm_group_label>
    <arm_group_label>Remicade, switch to CT-P13</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with active Crohn's disease and a Crohn's disease activity
             index score between 220 and 450 points

        Exclusion Criteria:

          -  Patient who has previously received a biological agent for the treatment of Crohn's
             disease.

          -  Patient who has allergies to any of the excipients of infliximab, any other murine
             and/or human proteins, or patient with a hypersensitivity to immunoglobulin product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nashville Medical Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 28, 2017</lastchanged_date>
  <firstreceived_date>March 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
